The Future of Cancer Medicine: Personal or Industrial?

The Future of Cancer Medicine: Personal or Industrial?

Publication date: Apr 13, 2019

The myriad of new signals that characterize the complex biology of cancer is compounded by the diversity of the human form.

Characterizing the human ‘phenome’ – the detailed description of the patient and their biological state – is becoming critical for accurate prediction of clinical outcomes of a given therapy and is associated with the development of ‘precision’ or ‘personalized’ cancer medicines.

The implications are important across all of cancer medicine and align with the need for improvements in patient safety, quality of care, clinical outcomes, and patient experience.

Concepts Keywords
Ad Hoc Patient safety
Automation Personalized medicine
Biomarkers Medical signs
Cognition Branches of biology
Digital Transformation Biotechnology
Genome Chemical pathology
Healthcare Biomarkers
Medicine Medicine
Paradox Manufacturing
Patient Safety Genome imaging
San Diego
Sequencing
Speaker

Semantics

Type Source Name
disease MESH Cancer
disease DOID Cancer
disease MESH development
disease MESH diagnosis
gene UNIPROT FURIN
gene UNIPROT NAA50

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *